origin
develop
commerci
antiprotozo
agent
nitazoxanid
later
identifi
firstinclass
broadspectrum
antivir
drug
repurpos
treatment
influenza
phase
clinic
trial
recent
publish
lancet
infecti
diseas
found
oral
administr
nitazoxanid
mg
twice
daili
five
day
reduc
durat
clinic
symptom
reduc
viral
shed
compar
placebo
person
laboratoryconfirm
influenza
studi
also
suggest
potenti
benefit
subject
influenzalik
ill
influenza
document
respiratori
viral
infect
chemic
perspect
nitazoxanid
scaffold
new
class
drug
call
thiazolid
smallmolecul
drug
target
hostregul
process
involv
viral
replic
nitazoxanid
oral
bioavail
safe
extens
postmarket
experi
involv
million
adult
children
new
dosag
formul
nitazoxanid
present
undergo
global
phase
clinic
develop
treatment
influenza
nitazoxanid
inhibit
broad
rang
influenza
b
virus
includ
influenza
avian
well
virus
resist
neuraminidas
inhibitor
synergist
neuraminidas
inhibitor
combin
therapi
oseltamivir
studi
human
part
ongo
phase
clinic
develop
nitazoxanid
also
inhibit
replic
broad
rang
rna
dna
virus
includ
respiratori
syncyti
viru
parainfluenza
coronaviru
rotaviru
noroviru
hepat
b
hepat
c
dengu
yellow
fever
japanes
enceph
viru
human
immunodefici
viru
cell
cultur
assay
clinic
trial
indic
potenti
role
thiazolid
treat
rotaviru
noroviru
gastroenter
chronic
hepat
b
chronic
hepat
c
ongo
futur
clinic
develop
focus
viral
respiratori
infect
viral
gastroenter
emerg
infect
dengu
fever
recent
year
desir
new
broadspectrum
antivir
drug
emphas
mean
provid
greater
protect
rang
virus
mitig
risk
resist
reduc
cost
associ
develop
drug
target
everi
specif
viru
shaw
diarmond
farzan
debe
et
al
zhou
simmon
view
constant
threat
caus
new
emerg
strain
influenza
limit
exist
drug
particular
need
drug
new
mechan
action
may
use
alon
combin
neuraminidas
inhibitor
provid
optim
medic
countermeasur
season
pandem
influenza
context
repurpos
nitazoxanid
treatment
influenza
could
prove
import
nitazoxanid
acetyloxi
n
benzamid
fig
first
synthes
earli
scaffold
niclosamid
replac
one
benzen
ring
ring
heterocycl
nitrothiazol
ring
heterocycl
rossignol
cavier
initi
nitazoxanid
develop
oral
antiparasit
agent
studi
activ
protozoan
helminth
infect
vitro
andor
vivo
mice
cat
dog
sheep
cavier
rossignol
euzebi
et
al
first
studi
human
treatment
intestin
cestod
rossignol
maisonneuv
later
nitazoxanid
found
effect
cell
cultur
assay
sever
anim
model
emerg
intracellular
protozoan
cryptosporidium
parvum
blagburn
et
al
theodo
et
al
li
et
al
baishanbo
et
al
licens
unit
state
alinia
romark
laboratori
orphan
drug
treatment
diarrhea
caus
c
parvum
giardia
intestinali
adult
children
least
month
age
ortiz
et
al
amadi
et
al
rossignol
et
al
first
remain
fdaapprov
treatment
cryptosporidium
infect
nitazoxanid
also
wide
commerci
latin
america
india
indic
treat
broad
spectrum
intestin
parasit
infect
addit
antiparasit
activ
nitazoxanid
activ
circul
metabolit
tizoxanid
fig
rossignol
stachulski
activ
vitro
broad
rang
oblig
facult
anaerob
gram
posit
gram
neg
bacteria
dubreuil
et
al
et
al
pankuch
appelbaum
hecht
et
al
finegold
et
al
freeman
et
al
well
replic
nonrepl
strain
mycobacterium
tuberculosi
de
carvalho
et
al
anim
studi
random
clinic
trial
confirm
activ
drug
treat
clostridium
difficil
diseas
mcvay
rolf
musher
et
al
musher
et
al
hoffman
et
al
studi
mechan
action
nitazoxanid
anaerob
bacteria
protozoa
show
nitazoxanid
inhibit
pyruv
ferredoxin
oxidoreductas
pfor
enzymedepend
electron
transfer
reaction
essenti
anaerob
energi
metabol
studi
tuberculosi
shown
nitazoxanid
act
uncoupl
disrupt
membran
potenti
intraorgan
ph
homeostasi
de
carvalho
et
al
licens
unit
state
nitazoxanid
subject
extens
pharmacolog
test
safeti
anim
human
romark
laboratori
recent
clinic
trial
evalu
cardiac
safeti
human
show
effect
cardiac
repolar
taubel
et
al
estim
million
adult
children
expos
nitazoxanid
postmarket
experi
treat
intestin
parasit
infect
without
signific
drugrel
safeti
issu
clinic
trial
postmarket
experi
nitazoxanid
use
primarili
treat
intestin
infect
treat
system
infect
anim
model
human
challeng
poor
solubl
drug
short
elimin
halflif
follow
oral
administr
nitazoxanid
activ
pharmaceut
ingredi
absorb
intestin
tract
rapidli
hydrolyz
plasma
esteras
form
tizoxanid
activ
circul
metabolit
glucuronoconjug
liver
drug
elimin
urin
bile
tizoxanid
tizoxanid
glucuronid
halflif
tizoxanid
plasma
approxim
h
circul
tizoxanid
bound
plasma
protein
broekhuysen
et
al
romark
laboratori
recent
year
laboratori
studi
reveal
broadspectrum
antivir
activ
nitazoxanid
round
remark
broad
spectrum
activ
drug
prompt
effort
develop
nitazoxanid
thiazolid
new
class
antivir
agent
new
controlledreleas
pharmaceut
formul
nitazoxanid
develop
deliv
drug
system
drug
repurpos
new
broadspectrum
agent
novel
mechan
action
treatment
influenza
review
antivir
activ
nitazoxanid
thiazolid
report
cell
cultur
assay
anim
studi
human
clinic
trial
emphasi
influenza
tizoxanid
activ
circul
metabolit
nitazoxanid
inhibit
replic
strain
influenza
one
strain
influenza
b
tabl
influenza
virus
sensit
tizoxanid
ic
rang
lgml
tabl
use
singl
step
viru
growth
high
multipl
infect
pfucel
multistep
viru
growth
low
multipl
infect
pfucel
antivir
activ
determin
h
singl
step
assay
h
multistep
assay
tissu
cultur
infecti
dose
tcid
andor
hemagglutin
assay
ic
tizoxanid
similar
influenza
cultur
differ
canin
human
cell
line
mdck
cell
monocyt
tlymphocyt
jurkat
alveolar
type
iilik
rossignol
et
al
ashton
et
al
belardo
et
al
sleeman
et
al
gubareva
et
al
combin
nitazoxanid
oseltamivir
zanamivir
synergist
test
influenza
avian
combin
index
valu
rang
independ
multipl
infect
use
belardo
et
al
observ
hepat
c
viru
korba
et
al
tizoxanid
high
barrier
resist
influenza
viru
decreas
sensit
observ
virus
passag
day
increas
concentr
lgml
tizoxanid
belardo
et
al
tizoxanid
also
inhibit
replic
parainfluenza
sendai
viru
ic
lgml
respiratori
syncyti
viru
ic
lg
ml
canin
coronaviru
ic
lgml
drug
show
activ
vitro
human
rhinoviru
type
tabl
peak
trough
plasma
concentr
tizoxanid
lgml
lgml
respect
twice
daili
dose
nitazoxanid
control
releas
tablet
phase
clinic
trial
haffizulla
et
al
concentr
suitabl
treat
viral
respiratori
infect
caus
influenza
virus
vitro
ic
typic
lgml
studi
mechan
action
nitazoxanid
influenza
virus
shown
drug
block
matur
viral
hemagglutinin
posttransl
stage
rossignol
et
al
drug
effect
glycoprotein
neuraminidas
target
oseltamivir
zanamivir
protein
target
amantadin
effect
viral
infect
adsorpt
entri
target
cell
la
frazia
et
al
rossignol
et
al
shi
et
al
peripher
blood
mononuclear
cell
pbmc
stimul
influenza
viru
nitazoxanid
potenti
product
type
interferon
alpha
beta
produc
host
fibroblast
clerici
et
al
signific
activ
fulli
understood
could
contribut
antivir
activ
nitazoxanid
interf
matur
hemagglutinin
glycoprotein
anoth
secondari
mechan
action
phase
random
doubleblind
placebocontrol
clinic
trial
conduct
unit
state
evalu
safeti
efficaci
nitazoxanid
mg
controlledreleas
tablet
adult
adolesc
least
year
age
acut
uncompl
influenza
subject
fever
least
one
respiratori
symptom
one
constitut
symptom
influenza
enrol
within
h
symptom
onset
randomli
assign
receiv
treatment
placebo
mg
nitazoxanid
mg
nitazoxanid
twice
daili
five
day
primari
efficaci
analysi
time
first
dose
allevi
symptom
subject
laboratoryconfirm
influenza
baselin
subject
receiv
nitazoxanid
experienc
shorter
time
allevi
symptom
mg
median
h
ci
p
mg
median
h
ci
p
subject
receiv
placebo
median
h
ci
fig
lack
statist
signific
level
low
dose
group
may
due
lack
statist
power
haffizulla
et
al
influenzainfect
subject
receiv
nitazoxanid
mg
also
show
signific
reduct
p
tcid
viral
titer
treatment
compar
subject
receiv
placebo
fig
resist
observ
influenza
virus
collect
nitazoxanidetr
subject
advers
effect
humor
immun
respons
observ
advers
event
similar
three
treatment
group
tabl
haffizulla
et
al
respons
similar
subject
infect
influenza
influenza
b
contrast
neuraminidas
inhibitor
treatment
nitazoxanid
also
significantli
reduc
durat
flulik
symptom
h
reduct
time
allevi
symptom
mg
vs
placebo
p
subject
unknown
viral
etiolog
haffizulla
et
al
phase
clinic
trial
design
accord
current
fda
guidanc
develop
new
drug
treat
influenza
regulatori
perspect
placebocontrol
trial
requir
clearli
demonstr
drugeffect
ethic
consider
placebocontrol
trial
conduct
subject
complic
ill
risk
complic
trial
design
gener
consist
previou
clinic
trial
oseltamivir
zanamivir
inher
difficult
compar
result
trial
clinic
trial
neuraminidas
inhibitor
conduct
fifteen
twenti
year
ago
reduct
symptom
durat
mg
dose
group
compar
placebo
h
rang
observ
similar
trial
neuraminidas
inhibitor
magnitud
treatment
effect
observ
differ
clinic
trial
could
influenc
studi
design
eg
popul
select
analysi
use
acetaminophen
symptom
relief
medic
characterist
circul
influenza
strain
eg
pathogen
drug
suscept
given
trial
exampl
phase
trial
enrol
subject
within
h
onset
symptom
studi
neuraminidas
inhibitor
typic
enrol
subject
within
h
symptom
onset
subject
enrol
within
h
symptom
onset
median
improv
time
symptom
allevi
nitazoxanid
mg
treatment
group
extend
h
larg
global
phase
clinic
trial
conduct
support
licensur
nitazoxanid
mg
controlledreleas
tablet
treatment
acut
uncompl
influenza
regist
clinicaltrialsgov
number
approxim
subject
influenza
symptom
random
one
four
treatment
arm
placebo
nitazoxanid
mg
oseltamivir
mg
nitazoxanid
mg
plu
oseltamivir
mg
twice
daili
five
day
primari
efficaci
endpoint
time
first
dose
allevi
symptom
coprimari
efficaci
analys
compar
time
first
dose
allevi
symptom
nitazoxanid
mg
group
placebo
group
ii
nitazoxanid
mg
plu
oseltamivir
mg
group
monotherapi
placebo
group
studi
conduct
contract
us
depart
health
human
servic
administ
biomed
advanc
research
develop
author
barda
studi
expect
provid
import
inform
relat
clinic
benefit
nitazoxanid
treat
uncompl
influenza
well
potenti
benefit
combin
drug
oseltamivir
date
approxim
subject
includ
trial
three
flu
season
one
northern
hemispher
two
southern
hemispher
expect
complet
influenza
season
northern
hemispher
notabl
phase
trial
largest
clinic
trial
ever
conduct
treatment
acut
uncompl
influenza
first
licensureen
clinic
trial
combin
drug
treat
influenza
first
new
registrationstyl
clinic
trial
oseltamivir
conduct
ten
year
futur
clinic
trial
nitazoxanid
expect
includ
patient
risk
influenza
complic
includ
comorbid
asthma
chronic
obstruct
pulmonari
diseas
copd
diabet
patient
year
age
children
year
age
clinic
trial
hospit
patient
sever
acut
respiratori
infect
sari
recent
initi
sponsorship
nation
institut
allergi
infecti
diseas
nation
institut
health
regist
clinicaltrialsgov
number
activ
tizoxanid
studi
use
eight
strain
rotaviru
cultur
three
differ
cell
line
tabl
work
molecular
virolog
carri
two
strain
rotaviru
simian
strain
human
strain
antivir
activ
observ
use
singlestep
viru
growth
high
moi
pfucel
multistep
viru
growth
low
moi
pfucel
singl
step
viru
growth
assay
use
monkey
kidney
cell
tizoxanid
inhibit
replic
simian
human
ic
lgml
respect
multistep
assay
ic
lgml
record
virus
cytotox
concentr
cc
cell
line
lgml
similar
result
obtain
use
human
gutderiv
cell
human
strain
viru
treatment
cell
lgml
tizoxanid
h
infect
rotaviru
protect
cell
viral
entri
tizoxanid
inhibit
viral
replic
cell
treat
h
postinfect
optim
activ
observ
tizoxanid
introduc
h
postinfect
la
frazia
et
al
fig
mean
chang
influenza
tcid
viral
titer
baselin
phase
clinic
trial
patient
uncompl
influenzalik
ill
analysi
chang
tcid
viral
titer
subject
confirm
influenza
particip
daili
nasopharyng
swab
collect
statist
comparison
use
mix
model
repeat
measur
includ
baselin
viral
titer
treatment
group
geograph
locat
p
differ
nitazoxanid
mg
placebo
p
differ
nitazoxanid
mg
placebo
haffizulla
et
al
reprint
permiss
elsevi
ic
ic
tizoxanid
noroviru
repliconassay
system
use
cell
line
lgml
respect
korba
person
commun
studi
shown
tizoxanid
inhibit
matur
rotaviru
viral
protein
glycoprotein
form
outer
part
virion
one
six
structur
glycoprotein
involv
rotaviru
replic
alter
viroplasm
format
interfer
viral
morphogenesi
la
frazia
et
al
two
phase
random
doubleblind
placebocontrol
studi
conduct
two
hundr
subject
viral
gastroenter
caus
rotaviru
noroviru
fifti
adult
adolesc
least
year
age
hospit
children
tabl
common
advers
event
treatment
group
report
phase
clinic
trial
involv
subject
acut
uncompl
influenzalik
ill
haffizulla
et
al
reprint
month
year
age
month
age
includ
two
studi
adult
adolesc
least
year
age
receiv
one
mg
nitazoxanid
tablet
one
match
placebo
tablet
twice
daili
three
consecut
day
children
year
age
receiv
mgml
suspens
match
placebo
administ
oral
dose
ml
year
age
ml
year
ml
month
twice
daili
three
day
nitazoxanid
significantli
reduc
durat
symptom
compar
placebo
adult
adolesc
infect
rotaviru
p
well
subject
infect
noroviru
p
rossignol
elgohari
likewis
children
rotaviru
gastroenter
treatment
nitazoxanid
significantli
reduc
durat
symptom
compar
placebo
p
rossignol
elgohari
anoth
studi
conduct
children
age
day
month
hospit
rotaviru
gastroenter
also
report
nitazoxanid
significantli
reduc
durat
ill
teran
et
al
success
treatment
noroviru
gastroenter
nitazoxanid
also
report
patient
leukemia
receiv
chemotherapi
hematopoiet
stem
cell
transplant
hsct
siddiq
et
al
larg
random
doubleblind
placebocontrol
clinic
trial
support
australian
nation
health
medic
research
council
nhmrc
conduct
aborigin
children
month
year
age
hospit
diarrhea
northern
territori
australia
sever
diarrhea
caus
cryptosporidium
parvum
rotaviru
noroviru
regist
clinicaltrialsgov
number
kaufman
et
al
recent
identifi
nitazoxanid
prospect
immedi
clinic
trial
immunocompromis
patient
infect
noroviru
tizoxanid
exhibit
select
inhibit
intracellular
hbv
extracellular
viru
product
cell
tabl
ic
lgml
record
tizoxanid
lamivudin
adefovir
dipovoxil
respect
select
indic
korba
et
al
openlabel
clinic
trial
nitazoxanid
administ
one
mg
tablet
twice
daili
consecut
month
twelv
adult
subject
chronic
hbv
four
hbeagposit
eight
hbeagneg
three
four
hbeag
posit
patient
becam
hbeagneg
averag
three
month
serum
hbv
dna
decreas
hbeagposit
patient
becam
neg
two
four
patient
importantli
one
patient
becam
hbsag
neg
clear
serum
hbv
dna
eight
hbeagneg
patient
seven
becam
hbv
dna
neg
two
patient
also
becam
hbsagneg
result
suggest
studi
warrant
determin
potenti
nitazoxanid
cure
hbvinfect
patient
tizoxanid
first
test
activ
hcv
genotyp
hcv
repliconcontain
cell
line
genotyp
hcv
repliconcontain
cell
line
tabl
genotyp
ic
ic
lgml
respect
select
index
cc
ic
genotyp
ic
ic
lgml
respect
select
index
cc
ic
combin
tizoxanid
interferon
c
methylcytidin
synergist
korba
et
al
potenti
resist
hcv
tizoxanid
studi
use
hcv
genotyp
repliconcontain
cell
line
subject
increas
concentr
tizoxanid
consecut
week
hcv
exhibit
reduc
suscept
tizoxanid
viral
genom
sequenc
show
mutat
characterist
resist
studi
suggest
hostdirect
mechan
action
high
barrier
viral
resist
korba
et
al
yon
et
al
mechanist
studi
effect
tizoxanid
replic
hepat
c
viru
cell
cultur
shown
activ
protein
kinas
r
pkr
import
part
innat
immun
respons
cell
expos
doublestrand
rna
turn
result
phosphoryl
eukaryot
initi
factor
gene
known
block
viral
replic
elazar
et
al
recent
studi
use
bovin
viral
diarrhea
viru
bvdv
surrog
hcv
infect
shown
nitazoxanid
inhibit
replic
cytopath
noncytopath
bvdv
mechan
like
involv
phosphoryl
pkr
author
also
observ
nitazoxanid
deplet
atpsensit
intracellular
ca
store
result
mild
endoplasm
reticulum
er
stress
disrupt
nlink
glycosyl
bvdv
structur
protein
ashiru
et
al
two
hundr
eighti
one
subject
infect
hcv
genotyp
three
genotyp
one
genotyp
total
subject
treat
part
seri
three
clinic
trial
conduct
egypt
first
random
doubleblind
placebocontrol
clinic
trial
conduct
adult
chronic
hepat
c
genotyp
studi
subject
receiv
one
nitazoxanid
tablet
mg
twice
daili
week
experienc
sustain
virolog
respons
svr
undetect
hcv
rna
serum
six
month
end
treatment
median
log
reduct
compar
none
subject
placebo
treatment
group
p
second
studi
conduct
adult
chronic
hepat
c
genotyp
administr
one
mg
nitazoxanid
tablet
twice
day
week
one
lg
inject
peginterferon
weekli
week
without
ribavirin
increas
svr
rate
without
ribavirin
respect
compar
obtain
one
weekli
lg
inject
peginterferon
ribavirin
standard
care
time
rossignol
et
al
openlabel
studi
adult
chronic
hepat
c
genotyp
three
genotyp
one
genotyp
subject
achiev
svr
treatment
nitazoxanid
monotherapi
week
follow
nitazoxanid
plu
peginterferon
without
ribavirin
week
four
subject
genotyp
experienc
svr
importantli
nitazoxanid
well
toler
subject
chronic
hepat
c
enrol
three
phase
studi
signific
addit
sideeffect
chang
laboratori
safeti
valu
caus
combin
peginterferon
ribavirin
carri
monthli
treatment
clinic
trial
indic
improv
respons
nitazoxanid
administ
combin
peginterferon
treatment
chronic
hepat
c
develop
discontinu
due
develop
new
direct
act
antivir
drug
combin
nitazoxanid
thiazolid
directact
antivir
drug
treat
chronic
hepat
c
andor
hiv
may
path
futur
develop
tizoxanid
shown
inhibit
replic
three
flavivirida
dengu
viru
type
japanes
enceph
viru
jev
yellow
fever
viru
yfv
cell
cultur
assay
tizoxanid
inhibit
replic
yfv
vero
cell
ic
lgml
respect
select
indic
respect
shown
tabl
menes
et
al
shi
et
al
report
nitazoxanid
inhibit
replic
jev
cell
ic
lgml
select
index
nitazoxanid
directli
affect
viral
infect
adsorpt
entri
target
cell
effect
cell
treat
h
postinfect
decreas
antivir
activ
cell
treat
h
postinfect
find
consist
studi
use
influenza
viru
rotaviru
rossignol
et
al
la
frazia
et
al
mice
challeng
lethal
dose
jev
mg
kg
nitazoxanid
administ
oral
gavag
daili
consecut
day
mice
surviv
observ
mgkgday
respect
untreat
mice
die
studi
day
public
tan
et
al
report
nitazoxanid
tizoxanid
inhibit
hiv
replic
ic
approxim
lgml
use
enzymelink
immunosorb
assay
elisa
pbmc
author
describ
novel
drug
screen
method
use
identifi
strongli
efficaci
synergist
drug
pair
overal
goal
expand
current
antiretrovir
repertoir
author
report
nitazoxanid
synerg
known
hiv
drug
integras
inhibitor
nucleosid
nonnucleosid
revers
transcript
inhibitor
exert
antivir
effect
entri
revers
transcript
larg
number
thiazolid
close
relat
chemic
structur
nitazoxanid
synthes
test
activ
parasit
bacteria
virus
stachulski
et
al
stachulski
et
al
two
compound
nitazoxanid
select
complet
develop
fig
new
thiazolid
deriv
nitro
group
thiazol
ring
chemic
structur
replac
chlorid
activ
anaerob
protozoa
bacteria
activ
cell
cultur
vivo
cryptosporidium
parvum
shown
broad
spectrum
activ
hbv
hcv
similar
nitazoxanid
gargala
et
al
gargala
et
al
korba
et
al
better
absorb
gastrointestin
tract
nitazoxanid
better
toler
anim
toxicolog
studi
administ
rat
dog
consecut
day
safeti
nitazoxanid
broadspectrum
antivir
activ
suggest
larg
number
altern
indic
could
explor
clinic
develop
next
five
year
clinic
develop
nitazoxanid
like
focu
primarili
viral
respiratori
infect
clinic
trial
special
popul
influenza
influenzalik
ill
requir
evalu
benefit
drug
hospit
patient
pediatr
patient
person
risk
influenza
complic
view
larg
amount
safeti
data
nitazoxanid
children
studi
pediatr
patient
year
age
like
proceed
quickli
follow
complet
ongo
phase
trial
studi
young
children
influenzalik
ill
like
enrol
larg
number
rsv
infect
specif
studi
children
rsv
infect
may
also
warrant
present
approv
antivir
treatment
influenza
hospit
patient
person
risk
complic
flu
furthermor
random
control
trial
patient
popul
proven
difficult
design
conduct
due
number
factor
includ
inabl
use
placebo
underli
ill
drug
efficaci
etc
synergist
activ
nitazoxanid
oseltamivir
cell
cultur
confirm
ongo
phase
clinic
trial
subject
acut
uncompl
influenza
data
may
suggest
path
design
conduct
clinic
trial
combin
compar
nitazoxanid
monotherapi
oseltamivir
monotherapi
treat
patient
hospit
influenza
new
viral
respiratori
infect
mer
coronaviru
emerg
develop
anim
model
perhap
clinic
trial
studi
activ
nitazoxanid
envis
preclin
studi
evalu
efficaci
drug
mer
coronaviru
ongo
given
histori
use
treat
broad
rang
intestin
infect
data
phase
clinic
trial
patient
rotaviru
noroviru
gastroenter
rational
addit
studi
nitazoxanid
broader
rang
infecti
diarrheal
ill
includ
rotaviru
noroviru
strong
studi
conduct
pediatr
patient
peru
shown
empir
treatment
diarrheal
ill
children
region
significantli
reduc
durat
ill
compar
placebo
rossignol
et
al
ongo
studi
aborigin
children
support
australian
nhmrc
expect
provid
addit
data
relat
use
treat
diarrheal
ill
includ
viral
gastroenter
similar
studi
may
expect
view
grow
recognit
import
cryptosporidium
well
rotaviru
noroviru
caus
diarrhea
children
studi
nitazoxanid
treatment
noroviru
immunocompromis
patient
suggest
kaufman
et
al
like
view
need
treatment
popul
asid
advanc
develop
nitazoxanid
treat
viral
respiratori
infect
viral
gastroenter
emerg
dengu
fever
perhap
viral
diseas
may
provid
path
clinic
develop
nitazoxanid
thiazolid
rossignol
inventor
led
develop
nitazoxanid
thiazolid
employe
own
equiti
interest
romark
laboratori
lc
